Cargando…
Glycogen synthase kinase-3β regulates fractalkine production by altering its trafficking from Golgi to plasma membrane: implications for Alzheimer’s disease
Glycogen synthase kinase-3β (GSK-3β) is a serine-threonine kinase implicated in multiple processes and signaling pathways. Its dysregulation is associated with different pathological conditions including Alzheimer’s disease (AD). Here we demonstrate how changes in GSK-3β activity and/or levels regul...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5309299/ https://www.ncbi.nlm.nih.gov/pubmed/27832289 http://dx.doi.org/10.1007/s00018-016-2408-6 |
_version_ | 1782507686377553920 |
---|---|
author | Fuster-Matanzo, Almudena Jurado-Arjona, Jerónimo Benvegnù, Stefano García, Esther Martín-Maestro, Patricia Gómez-Sintes, Raquel Hernández, Félix Ávila, Jesús |
author_facet | Fuster-Matanzo, Almudena Jurado-Arjona, Jerónimo Benvegnù, Stefano García, Esther Martín-Maestro, Patricia Gómez-Sintes, Raquel Hernández, Félix Ávila, Jesús |
author_sort | Fuster-Matanzo, Almudena |
collection | PubMed |
description | Glycogen synthase kinase-3β (GSK-3β) is a serine-threonine kinase implicated in multiple processes and signaling pathways. Its dysregulation is associated with different pathological conditions including Alzheimer’s disease (AD). Here we demonstrate how changes in GSK-3β activity and/or levels regulate the production and subsequent secretion of fractalkine, a chemokine involved in the immune response that has been linked to AD and to other different neurological disorders. Treatment of primary cultured neurons with GSK-3β inhibitors such as lithium and AR-A014418 decreased full-length fractalkine in total cell extracts. Opposite effects were observed after neuron transduction with a lentiviral vector overexpressing the kinase. Biotinylation assays showed that those changes mainly affect the plasma membrane-associated form of the protein, an observation that positively correlates with changes in the levels of its soluble form. These effects were confirmed in lithium-treated wild type (wt) mice and in GSK-3β transgenic animals, as well as in brain samples from AD patients, evident as age-dependent (animals) or Braak stage dependent changes (humans) in both the membrane-bound and the soluble forms of the protein. Further immunohistochemical analyses demonstrated how GSK-3β exerts these effects by affecting the trafficking of the chemokine from the Golgi to the plasma membrane, in different and opposite ways when the levels/activity of the kinase are increased or decreased. This work provides for the first time a mechanism linking GSK-3β and fractalkine both in vitro and in vivo, with important implications for neurological disorders and especially for AD, in which levels of this chemokine might be useful as a diagnostic tool. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00018-016-2408-6) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5309299 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-53092992017-02-28 Glycogen synthase kinase-3β regulates fractalkine production by altering its trafficking from Golgi to plasma membrane: implications for Alzheimer’s disease Fuster-Matanzo, Almudena Jurado-Arjona, Jerónimo Benvegnù, Stefano García, Esther Martín-Maestro, Patricia Gómez-Sintes, Raquel Hernández, Félix Ávila, Jesús Cell Mol Life Sci Original Article Glycogen synthase kinase-3β (GSK-3β) is a serine-threonine kinase implicated in multiple processes and signaling pathways. Its dysregulation is associated with different pathological conditions including Alzheimer’s disease (AD). Here we demonstrate how changes in GSK-3β activity and/or levels regulate the production and subsequent secretion of fractalkine, a chemokine involved in the immune response that has been linked to AD and to other different neurological disorders. Treatment of primary cultured neurons with GSK-3β inhibitors such as lithium and AR-A014418 decreased full-length fractalkine in total cell extracts. Opposite effects were observed after neuron transduction with a lentiviral vector overexpressing the kinase. Biotinylation assays showed that those changes mainly affect the plasma membrane-associated form of the protein, an observation that positively correlates with changes in the levels of its soluble form. These effects were confirmed in lithium-treated wild type (wt) mice and in GSK-3β transgenic animals, as well as in brain samples from AD patients, evident as age-dependent (animals) or Braak stage dependent changes (humans) in both the membrane-bound and the soluble forms of the protein. Further immunohistochemical analyses demonstrated how GSK-3β exerts these effects by affecting the trafficking of the chemokine from the Golgi to the plasma membrane, in different and opposite ways when the levels/activity of the kinase are increased or decreased. This work provides for the first time a mechanism linking GSK-3β and fractalkine both in vitro and in vivo, with important implications for neurological disorders and especially for AD, in which levels of this chemokine might be useful as a diagnostic tool. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00018-016-2408-6) contains supplementary material, which is available to authorized users. Springer International Publishing 2016-11-10 2017 /pmc/articles/PMC5309299/ /pubmed/27832289 http://dx.doi.org/10.1007/s00018-016-2408-6 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Fuster-Matanzo, Almudena Jurado-Arjona, Jerónimo Benvegnù, Stefano García, Esther Martín-Maestro, Patricia Gómez-Sintes, Raquel Hernández, Félix Ávila, Jesús Glycogen synthase kinase-3β regulates fractalkine production by altering its trafficking from Golgi to plasma membrane: implications for Alzheimer’s disease |
title | Glycogen synthase kinase-3β regulates fractalkine production by altering its trafficking from Golgi to plasma membrane: implications for Alzheimer’s disease |
title_full | Glycogen synthase kinase-3β regulates fractalkine production by altering its trafficking from Golgi to plasma membrane: implications for Alzheimer’s disease |
title_fullStr | Glycogen synthase kinase-3β regulates fractalkine production by altering its trafficking from Golgi to plasma membrane: implications for Alzheimer’s disease |
title_full_unstemmed | Glycogen synthase kinase-3β regulates fractalkine production by altering its trafficking from Golgi to plasma membrane: implications for Alzheimer’s disease |
title_short | Glycogen synthase kinase-3β regulates fractalkine production by altering its trafficking from Golgi to plasma membrane: implications for Alzheimer’s disease |
title_sort | glycogen synthase kinase-3β regulates fractalkine production by altering its trafficking from golgi to plasma membrane: implications for alzheimer’s disease |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5309299/ https://www.ncbi.nlm.nih.gov/pubmed/27832289 http://dx.doi.org/10.1007/s00018-016-2408-6 |
work_keys_str_mv | AT fustermatanzoalmudena glycogensynthasekinase3bregulatesfractalkineproductionbyalteringitstraffickingfromgolgitoplasmamembraneimplicationsforalzheimersdisease AT juradoarjonajeronimo glycogensynthasekinase3bregulatesfractalkineproductionbyalteringitstraffickingfromgolgitoplasmamembraneimplicationsforalzheimersdisease AT benvegnustefano glycogensynthasekinase3bregulatesfractalkineproductionbyalteringitstraffickingfromgolgitoplasmamembraneimplicationsforalzheimersdisease AT garciaesther glycogensynthasekinase3bregulatesfractalkineproductionbyalteringitstraffickingfromgolgitoplasmamembraneimplicationsforalzheimersdisease AT martinmaestropatricia glycogensynthasekinase3bregulatesfractalkineproductionbyalteringitstraffickingfromgolgitoplasmamembraneimplicationsforalzheimersdisease AT gomezsintesraquel glycogensynthasekinase3bregulatesfractalkineproductionbyalteringitstraffickingfromgolgitoplasmamembraneimplicationsforalzheimersdisease AT hernandezfelix glycogensynthasekinase3bregulatesfractalkineproductionbyalteringitstraffickingfromgolgitoplasmamembraneimplicationsforalzheimersdisease AT avilajesus glycogensynthasekinase3bregulatesfractalkineproductionbyalteringitstraffickingfromgolgitoplasmamembraneimplicationsforalzheimersdisease |